Search

Dihua Yu

from Houston, TX
Age ~66
Get Report
Also known as:
Dihua Y Tian
Phone and address:
2615 Quenby Ave, Houston, TX 77005
(713) 240-5630
Related to:
Charles Tian, 32Clara Tian, 26Ping Tian, 69
Connected to:
Abigail M Yu, 42Adeline Y Yu, 40Ai Yu, 64Aimy Yu, 30Aiping A Yu, 70Alisa Yu, 34Allen Yu, 29Angelia W Yu, 74Angelita T Yu, 68Anna Yu, 56

Dihua Yu Phones & Addresses

  • 2615 Quenby Ave, Houston, TX 77005 (713) 240-5630
  • 2615 Quenby St, Houston, TX 77005
  • West University Place, TX
  • Dallas, TX

Work

Company: U.t. m. d. anderson cancer center Position: Professor

Education

School / High School: The University of Texas Health Science Center at Houston 1986 to 1991

Skills

Cancer • Biochemistry • Cell Biology • Research • Western Blotting • Immunohistochemistry • Molecular Biology • Pcr • Life Sciences • Genetics • Cell Culture • Cancer Research

Industries

Higher Education

Resumes

Resumes

Dihua Yu Photo 1

Professor

View page
Location:
Houston, TX
Industry:
Higher Education
Work:
U.T. M. D. Anderson Cancer Center
Professor
Education:
The University of Texas Health Science Center at Houston 1986 - 1991
Skills:
Cancer
Biochemistry
Cell Biology
Research
Western Blotting
Immunohistochemistry
Molecular Biology
Pcr
Life Sciences
Genetics
Cell Culture
Cancer Research

Business Records

Name / Title
Company / Classification
Phones & Addresses
Dihua Yu
Director, President
SOCIETY OF CHINESE BIOSCIENTISTS IN AMERICA
2501 Swift Blvd, Houston, TX 77030

Publications

Us Patents

Mini-E1A Gene And Gene Products

View page
US Patent:
6683059, Jan 27, 2004
Filed:
Nov 21, 2000
Appl. No.:
09/718865
Inventors:
Mien-Chie Hung - Houston TX
Hua Chen - Houston TX
Dihua Yu - Houston TX
Ralph Wilfred Paul - Seattle WA
Aaron Garth Loomis - Seattle WA
Daniel Nathan Andrew LaFoc - Seattle WA
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A01N 4304
US Classification:
514 44, 4353201, 435325, 424 9321
Abstract:
The present invention provides methods and compositions for the suppression of oncogenic transformation, tumorigenesis and metastasis. The present invention discloses functional domains of E1A responsible for the suppression of transformation, and provides mini-E1A constructs that can be used for tumor suppression. The invention also discloses methods for the novel use of mini-E1A in combination with chemotherapeutic drugs and/or tyrosine kinase inhibitors.

14-3-3 Zeta Over-Expression As A Poor Prognosis Factor, And A Therapeutic Target In Multiple Cancer Types

View page
US Patent:
7316907, Jan 8, 2008
Filed:
Sep 10, 2004
Appl. No.:
10/938387
Inventors:
Dihua Yu - Houston TX, US
Jun Yao - Chestnut Hill MA, US
Christopher L. Neal - Houston TX, US
Wentao Yang - Shanghai, CN
Xiaoyan Zhou - Shanghai, CN
Raphael E. Pollock - Houston TX, US
Mien-Chie Hung - Houston TX, US
Jun Yang - Houston TX, US
Ping Li - Houston TX, US
Nina T. Nguyen - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 33/53
G01N 33/574
US Classification:
435 71, 435 723
Abstract:
Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

14-3-3 Zeta Over-Expression As A Poor Prognosis Factor, And A Therapeutic Target In Multiple Cancer Type

View page
US Patent:
7709205, May 4, 2010
Filed:
Dec 4, 2007
Appl. No.:
11/950264
Inventors:
Dihua Yu - Houston TX, US
Jun Yao - Chestnut Hill MA, US
Christopher L. Neal - Houston TX, US
Wentao Yang - Shanghai, CN
Xiaoyan Zhou - Shanghai, CN
Raphael E. Pollock - Houston TX, US
Mien-Chie Hung - Houston TX, US
Jun Yang - Houston TX, US
Ping Li - Houston TX, US
Nina T. Nguyen - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

Diagnostic And Therapeutic Methods And Compositions Involving Pten And Breast Cancer

View page
US Patent:
7981618, Jul 19, 2011
Filed:
Nov 5, 2004
Appl. No.:
10/983011
Inventors:
Dihua Yu - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Assignee:
Board of Regents of The University of Texas System - Austin TX
International Classification:
C12Q 1/00
G01N 1/00
G01N 33/48
G01N 33/53
G01N 33/567
G01N 33/574
US Classification:
435 71, 435 4, 435 721, 435 723, 436 63, 436 64, 436174
Abstract:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

Diagnostic And Therapeutic Methods And Compositions Involving Pten And Breast Cancer

View page
US Patent:
20110150868, Jun 23, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/943644
Inventors:
Dihua Yu - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Assignee:
Board of Regents of The University of Texas System - Austin TX
International Classification:
A61K 39/395
A61P 35/00
C12Q 1/68
G01N 33/573
C12Q 1/42
US Classification:
4241331, 435 611, 435 613, 435 723, 435 21
Abstract:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

Diagnostic And Therapeutic Methods And Compositions Involving Pten And Breast Cancer

View page
US Patent:
20120039875, Feb 16, 2012
Filed:
Jul 15, 2011
Appl. No.:
13/184269
Inventors:
Dihua Yu - Houston TX, US
Xiaoyan Zhou - Shanghai, CN
Yoichi Nagata - Tosu, JP
Francisco J. Esteva - Bellaire TX, US
Aysegul A. Sahin - Houston TX, US
Assignee:
Board of Regents of The University of Texas System - Austin TX
International Classification:
A61K 39/395
A61P 35/00
C12Q 1/68
US Classification:
4241331, 435 611
Abstract:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

Methods And Compositions For Predicting Cancer Therapy Response

View page
US Patent:
20130005592, Jan 3, 2013
Filed:
Sep 10, 2010
Appl. No.:
13/394936
Inventors:
Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Darl Flake - Salt Lake City UT, US
Francisco J. Esteva - Houston TX, US
Dihua Yu - Houston TX, US
Assignee:
Board of Regents of the University of Texas System - Austin TX
Myriad Genetics Incorporated - Salt Lake City UT
International Classification:
C40B 30/04
C12Q 1/68
G01N 33/574
C07H 21/04
US Classification:
506 9, 536 2431, 435 611, 435 792, 435 71, 435 723
Abstract:
The invention generally relates to molecular diagnostics, and particularly to molecular markers for cancer therapy response and methods of use thereof.

Suppression Of Neu Overexpression Using A Mini-E1A Gene

View page
US Patent:
63263564, Dec 4, 2001
Filed:
Oct 18, 1996
Appl. No.:
8/730910
Inventors:
Hua Chen - Houston TX
Dihua Yu - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 3170
A61K 4800
A61K 9127
A01N 6300
US Classification:
514 44
Abstract:
The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185 neu tyrosine kinase. Over-expression of the neu oncogene can lead to chemoresistance. The present invention discloses the functional domains of E1A responsible for the repression of neu-mediated transformation. Further the invention discloses methods for the novel use of mini-E1A in combination with chemotherapeutic drugs and/or tyrosine kinase inhibitors. Mini-E1A may be used in the treatment of cancer and other disease.
Control profile
Dihua Yu from Houston, TX, age ~66 Get Report